CABA Class Action: Learn About the Cabaletta Lawsuit

Levi & Korsinsky, LLP announces that a CABA class action lawsuit has been filed on behalf of investors who purchased Cabaletta Bio, Inc. (CABA) This lawsuit is on behalf of persons and entities that purchased or otherwise acquired: (a) Cabaletta common stock pursuant and/or traceable to documents issued in connection with the Company’s initial public offering conducted on or about October 24, 2019; and/or (b) Cabaletta securities between October 24, 2019, and December 13, 2021, For more on the CABA Lawsuit please contact us today.

Hot-stocks LK People

According to the Cabaletta lawsuit, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: (i) top-line data of the Phase 1 Clinical Trial indicated that Cabaletta’s lead product candidate, DSG3-CAART, had, among other things, worsened certain participants’ disease activity scores and necessitated additional systemic medication to improve disease activity after DSG3-CAART infusion; (ii) accordingly, DSG3-CAART was not as effective as the Company had represented to investors; (iii) therefore, the Company had overstated DSG3-CAART’s clinical and/or commercial prospects; and (iv) as a result, the Company’s public statements were materially false and misleading at all relevant times.

TO LEARN MORE ABOUT THE CABA CLASS ACTION LAWSUIT, CLICK HERE

If you suffered a loss in Cabaletta you have until April 29, 2022, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
55 Broadway, 10th Floor
New York, NY 10006
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com

You may also like...